# Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations

> **NCT05050149** · PHASE2 · COMPLETED · sponsor: **Palvella Therapeutics, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Microcystic Lymphatic Malformation

## Interventions

- **DRUG:** PTX-022

## Key facts

- **NCT ID:** NCT05050149
- **Lead sponsor:** Palvella Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-13
- **Primary completion:** 2022-11-15
- **Final completion:** 2022-12-15
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05050149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05050149, "Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05050149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*